Drug intelligence / Profile preview

iSCLife-UT

Development stage: Phase 1
Lead developer: Sclnow Biotechnology
Modality: Cell Therapies
Administration: Intrauterine

Overview

**iSCLife-UT** is an investigational allogeneic human umbilical cord mesenchymal stem cell (hUC-MSC) therapy developed for treating thin endometrium in women with infertility. Administered to promote endometrial regeneration and improve fertility outcomes, it leverages the immunomodulatory, anti-inflammatory, and regenerative properties of MSCs to repair endometrial tissue damaged by conditions like intrauterine adhesions or Asherman syndrome. The product is produced by SCLnow Biotechnology and studied in clinical trials in China, often in combination with standard care.[2][12][17]

Beyond the preview

Go deeper on iSCLife-UT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iSCLife-UT.

Explore the full profile